Class information for:
Level 1: RALOXIFENE//TISSUE SELECTIVE ESTROGEN COMPLEX//BAZEDOXIFENE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
8236 1205 40.3 82%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
232 19686 TAMOXIFEN//AROMATASE INHIBITORS//ANASTROZOLE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 RALOXIFENE Author keyword 114 32% 24% 290
2 TISSUE SELECTIVE ESTROGEN COMPLEX Author keyword 77 96% 2% 24
3 BAZEDOXIFENE Author keyword 68 69% 5% 59
4 OSPEMIFENE Author keyword 53 78% 3% 35
5 TSEC Author keyword 34 93% 1% 13
6 SELECTIVE ESTROGEN RECEPTOR MODULATOR Author keyword 33 36% 6% 73
7 LASOFOXIFENE Author keyword 26 64% 2% 25
8 SERM Author keyword 16 22% 5% 63
9 MIDLIFE HLTH Address 14 64% 1% 14
10 SERMS Author keyword 10 20% 4% 44

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 RALOXIFENE 114 32% 24% 290 Search RALOXIFENE Search RALOXIFENE
2 TISSUE SELECTIVE ESTROGEN COMPLEX 77 96% 2% 24 Search TISSUE+SELECTIVE+ESTROGEN+COMPLEX Search TISSUE+SELECTIVE+ESTROGEN+COMPLEX
3 BAZEDOXIFENE 68 69% 5% 59 Search BAZEDOXIFENE Search BAZEDOXIFENE
4 OSPEMIFENE 53 78% 3% 35 Search OSPEMIFENE Search OSPEMIFENE
5 TSEC 34 93% 1% 13 Search TSEC Search TSEC
6 SELECTIVE ESTROGEN RECEPTOR MODULATOR 33 36% 6% 73 Search SELECTIVE+ESTROGEN+RECEPTOR+MODULATOR Search SELECTIVE+ESTROGEN+RECEPTOR+MODULATOR
7 LASOFOXIFENE 26 64% 2% 25 Search LASOFOXIFENE Search LASOFOXIFENE
8 SERM 16 22% 5% 63 Search SERM Search SERM
9 SERMS 10 20% 4% 44 Search SERMS Search SERMS
10 SELECTIVE ESTROGEN RECEPTOR MODULATORS 10 22% 3% 39 Search SELECTIVE+ESTROGEN+RECEPTOR+MODULATORS Search SELECTIVE+ESTROGEN+RECEPTOR+MODULATORS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 VULVAR VAGINAL ATROPHY 72 100% 2% 23
2 ESTROGEN RECEPTOR MODULATOR 53 44% 8% 91
3 LY139481 HCL 50 88% 2% 23
4 RALOXIFENE 48 22% 16% 196
5 BOWEL PROJECT P 1 36 33% 7% 90
6 BAZEDOXIFENE CONJUGATED ESTROGENS 31 67% 2% 28
7 VERTEBRAL FRACTURE RISK 22 21% 8% 91
8 SERM 21 85% 1% 11
9 RECEPTOR MODULATOR 18 49% 2% 27
10 STAR P 2 TRIAL 17 41% 3% 33

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Selective estrogen receptor modulators (SERMs): A review of clinical data 2015 2 46 65%
Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review for the US Preventive Services Task Force 2013 20 95 77%
An overview of current and emerging SERMs 2014 13 119 56%
Use of SERMs for treatment in postmenopausal women 2014 11 96 55%
Selective estrogen receptor modulators: An update on recent clinical findings 2008 75 169 44%
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction 2009 103 100 41%
Recent advances help understand and improve the safety of menopausal therapies 2015 2 53 40%
Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis 2010 45 35 57%
Drug therapy: Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice 2003 405 88 22%
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence 2015 1 92 55%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MIDLIFE HLTH 14 64% 1.2% 14
2 E BAY PHYS MED GRP 2 67% 0.2% 2
3 LYNN SAGE BREAST CANC PROGRAM 2 33% 0.3% 4
4 SURG ADJUVANT BREAST BOWEL PROJECT 2 18% 0.7% 8
5 BREAST CANC MED 1 50% 0.2% 2
6 BASIC PREVENT SCI GRP 1 29% 0.3% 4
7 CLIN SERV TURKU 1 29% 0.3% 4
8 SURG ADJUVANT BREAST BOWEL PROJECT NSABP 1 30% 0.2% 3
9 GETULIO VARGAS HOSP 1 40% 0.2% 2
10 SECT CANC GENET PREVENT 1 40% 0.2% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000247765 TAMOXIFEN//TOREMIFENE//DROLOXIFENE
2 0.0000129087 SERAMS//MATH CHEM//ESTROGEN RECEPTOR LIGANDS
3 0.0000111005 HORMONE REPLACEMENT THERAPY//HORMONE THERAPY//TIMING HYPOTHESIS
4 0.0000104352 AROMATASE INHIBITORS//EXEMESTANE//ANASTROZOLE
5 0.0000099336 ENDOXIFEN//DESMETHYLTAMOXIFEN//N DESMETHYL TAMOXIFEN
6 0.0000095779 VAGINAL ATROPHY//UROGENITAL ATROPHY//VULVOVAGINAL ATROPHY
7 0.0000085277 ALENDRONATE//RISEDRONATE//BISPHOSPHONATES
8 0.0000079647 MAMMOGRAPHIC DENSITY//BREAST DENSITY//MAMMOGRAPHIC BREAST DENSITY
9 0.0000074707 9 CIS UAB30//NSC23925//TARGRETIN
10 0.0000065300 TIBOLONE//TIBOLONE METABOLITES//LIVIAL